AvalehtFTRE • NASDAQ
add
Fortrea Holdings Inc
19,73 $
Pärast sulgemist:(0,00%)0,00
19,73 $
Suletud: 22. nov, 16:16:10 GMT −5 · USD · NASDAQ · Välistus
Viimane sulgemishind
19,50 $
Tänane vahemik
19,18 $ - 20,14 $
Aasta vahemik
16,53 $ - 41,02 $
Turuväärtus
1,77 mld USD
Keskmine maht
1,32 mln
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 674,90 mln | −5,45% |
Põhitegevusega seonduv kulu | 157,50 mln | 21,53% |
Puhastulu | −27,90 mln | −99,29% |
Puhaskasumimarginaal | −4,13 | −110,71% |
Puhaskasum aktsia kohta | 0,23 | −4,17% |
EBITDA | 12,00 mln | −72,22% |
Tõhus maksumäär | 48,32% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 105,30 mln | −4,01% |
Kogu vara | 3,66 mld | −15,13% |
Kõik kohustused | 2,15 mld | −18,01% |
Kogu omakapital | 1,51 mld | — |
Emiteeritud aktsiate arv | 89,70 mln | — |
Hinna ja väärtuse suhe P/B | 1,16 | — |
Varade tasuvus | −0,64% | — |
Kapitali tasuvus | −0,85% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −27,90 mln | −99,29% |
Põhitegevuse rahakäive | −2,40 mln | −226,32% |
Investeeringute raha | −8,10 mln | −400,00% |
Finantseerimise raha | −14,00 mln | −81,82% |
Raha ja raha ekvivalentide muutus | −20,90 mln | −309,80% |
Tasuta rahavoog | −19,35 mln | −269,37% |
Teave
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Tegevjuht
Asutatud
apr 1996
Veebisait
Töötajate arv
15 500